Cyclosporin A [59865-13-3]

Minimum order 2

Cat# NB-64-01105-50mg

Size : 50mg

Brand : Neo Biotech


Cyclosporin A (Synonyms: Cyclosporine A, Cyclosporine, Ciclosporin)

Catalog No. T0945 Copy Product Info
Purity: 99.92%
Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.

Cyclosporin A

Copy Product Info
Synonyms Cyclosporine A, Cyclosporine, Ciclosporin

Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.

Cyclosporin A
Cas No. 59865-13-3
Select Batch
Purity:99.92%
Appearance:Solid
Color:White
Contact us for more batch information

Product Introduction

Bioactivity
Description
Cyclosporin A is a natural product and an active fungal metabolite, classified as a cyclic polypeptide immunosuppressant. It binds to cyclophilin and inhibits the activity of calcineurin (IC₅₀ = 7 nM) as well as CD11a/CD18 adhesion molecules. It is commonly used to induce uremia models.
Targets&IC50
CYP450 (Rat):0.4 μM (Ks), Calcineurin phosphatase:7 nM, U-87MG cells viability:10 μM
In vitro
METHODS: Glioma cell C6 was treated with Cyclosporin A (10 μM) under hypoxic conditions for 4 h. The expression levels of target proteins were measured by Western Blot.
RESULTS: 4 h hypoxia induced a large accumulation of endogenous HIF-1α protein, and Cyclosporin A prevented most of the hypoxia-induced HIF-1α stabilization. [1]
METHODS: Human colon cancer cells CACO-2 were treated with Cyclosporin A (2 μM) for 24-72 h. The cell cycle was detected by Flow Cytometry.
RESULTS: Accumulation of cells was detected in the G0/G1 phase after treatment with Cyclosporin A. The RESULTS were summarized in the following table. [2]
In vivo
METHODS: To assay activity against muscle disease in vivo, Cyclosporin A (5 mg/kg in olive oil) was injected intraperitoneally into myopathic Col6a1-/- mice twice daily for ten days.
RESULTS: Cyclosporin A affected satellite cell activity and triggered regenerative fiber formation in Col6a1-/- mice. [3]
METHODS: To detect the effects on ischemia-reperfusion injury (IRI), Cyclosporin A (3 mg/kg, 1 h or 10 min before ischemia; 10 mg/kg, 10 min before ischemia) was intraperitoneally injected into ischemia-reperfused C57BL/6J mice.
RESULTS: Mortality and renal function were significantly higher in the Cyclosporin A 10 mg/kg-10 min and Cyclosporin A 3 mg/kg-1 h groups than in the Cyclosporin A 3 mg/kg-10 min group. [4]
Disease Modeling Protocol
Chronic kidney disease model
  • Modeling Mechanism:

    Cyclosporin A (CsA) stimulates the transforming growth factor-β (TGF-β) signaling pathway, inducing renal interstitial fibroblast activation and epithelial-mesenchymal transition (EMT), promoting the deposition of extracellular matrix (ECM) components such as fibronectin (FN) and type I collagen (COL1A). Simultaneously, it inhibits ECM degradation mediated by matrix metalloproteinases (MMP2, MMP9), leading to renal tubular-interstitial fibrosis. Furthermore, CsA upregulates NADPH oxidase (NOX4) expression and downregulates superoxide dismutase (SOD2) activity, exacerbating oxidative stress (elevated DNA damage marker 8-OHdG) and activating lysozyme (LOX/LOXL2)-mediated ECM cross-linking, ultimately resulting in renal impairment.

  • Related Products:

    Cyclosporin A (T0945)

  • Modeling Method:

    Experimental Subject:

    Mice, C57BL/6J, 6–8 weeks of age

    Dosage and Administration Route:

    30 mg/kg/day cyclosporine A, subcutaneous injection (s.c.)
    Control treatment: Control mice received an equal volume of physiological saline solution by subcutaneous injection; all other treatments were identical

    Dosing Frequency and Duration Model:

    Once daily for 16 weeks

  • Validation:

    1. Functional Indicators: - Renal Function: Blood urea nitrogen (BUN) was significantly elevated (P<0.001), while the urine albumin/creatinine ratio (UACR) showed no significant increase, and plasma renal injury marker (KIM-1) levels showed no significant change. 2. Pathological Indicators: - Tissue Damage: Masson trichrome staining showed increased scores for renal tubular dilation, interstitial inflammation, and fibrosis (P<0.05), and PAS staining showed an increased glomerular sclerosis index (P<0.01). - Fibrosis: Sirius red (PSR) staining showed a significant increase in the area of type I/III collagen deposition (P<0.001), and upregulated expression of α-SMA (myofibroblast marker) protein (P<0.01). 3. Molecular Indicators: - Fibrosis-related Genes: Upregulated expression of LOX, LOXL2, TGF-β1, FN, and COL1A mRNA (P<0.01). - Inflammation and Oxidative Stress: TNFα and MCP-1... Increased mRNA and protein expression (P<0.05), upregulated NOX4 mRNA, downregulated SOD2 mRNA (P<0.05), and increased 8-OHdG level (P<0.001).

*Precautions: The mice were euthanized by cardiac puncture during deep anesthesia.

*References:Nguyen LT,et,al. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse. Sci Rep. 2021 Jun 14;11(1):12437.

Kinase Assay
Phosphatase Assay: Purified bovine brain calcineurin and calmodulin are purchased. Reaction mixtures with purified enzyme contains 100 nM calcineurin, 100 nM calmodulin, and 5 μM 32P-labeled phosphopeptide, in 60 μl (total volume) of assay buffer containing 20 mM Tris (pH 8), 100 mM NaCI, 6 mM MgCl2, 0.5 mM dithiothreitol, 0.1 mg of bovine serum albumin per ml, and either 0.1 mM CaCl2 or 5 mM EGTA. Reaction mixtures with cell lysates contains 20 μl of undiluted lysate, 5 μM 32P-labeled phosphopeptide, and 40 μl of assay buffer. Where indicated, reaction mixtures contains 50 μM peptide 412 or 413 and/or 500 nM okadaic acid, a specific inhibitor of phosphatases 1 and 2A; 500 nM okadaic acid is sufficient for inhibition of Ca2+-independent phosphatases, whereas higher concentrations partially inhibit Ca2+-dependent activity as well. After 15 min at 30°C, reactions are terminated by the addition of 0.5 ml of 100 mM potassium phosphate buffer (pH 7.0) containing 5% trichloroacetic acid. Free inorganic phosphate is isolated by Dowex cation-exchange chromatography and quantitated by scintillation counting as described.
Cell Research
Immunosuppressive agents are dissolved in ethanol at concentrations 1000-fold more than the concentration desired for cell treatments. Cells (106) are suspended in 1 ml of complete medium in microcentrifuge tubes; 1 μl of ethanol or of the ethanolic solution of Cyclosporin A is added, and the cells are incubated at 37°C for 1 hr. Cells are washed twice with 1 ml of PBS on ice and lysed in 50μl of hypotonic buffer containing 50 mM Tris (pH 7.5); 0.1 mM EGTA; 1 mM EDTA; 0.5 mM dithiothreitol; and 50 μg of phenylmethylsulfonyl fluoride, 50 μg of soybean trypsin inhibitor, 5 μg of leupeptin, and 5 μg of aprotinin per ml. Lysates are subjected to three cycles of freezing in liquid nitrogen followed by thawing at 30°C and then are centrifuged at 4°C for 10 min at 12,000×g.(Only for Reference)
SynonymsCyclosporine A, Cyclosporine, Ciclosporin
Chemical Properties
Molecular Weight1202.61
FormulaC62H111N11O12
Cas No.59865-13-3
Smiles[C@H]([C@@H](C/C=C/C)C)(O)[C@@]1(N(C)C(=O)[C@H]([C@@H](C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H]([C@H](C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)18
Relative Density.0.9913 g/cm3 (Estimated)
Storage & Solubility Information
StorageShipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 255 mg/mL (212.04 mM), Sonication is recommended.
Ethanol: 60.1 mg/mL (49.97 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 12.03 mg/mL (10 mM), Suspension.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
Ethanol/DMSO
1mg5mg10mg50mg
1 mM0.8315 mL4.1576 mL8.3152 mL41.5762 mL
5 mM0.1663 mL0.8315 mL1.6630 mL8.3152 mL
10 mM0.0832 mL0.4158 mL0.8315 mL4.1576 mL
20 mM0.0416 mL0.2079 mL0.4158 mL2.0788 mL
DMSO
1mg5mg10mg50mg
50 mM0.0166 mL0.0832 mL0.1663 mL0.8315 mL
100 mM0.0083 mL0.0416 mL0.0832 mL0.4158 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
NB-64-00249-50mg
 50mg 
NB-64-08193-5mg
 5mg 
NB-64-04846-10mg
 10mg